Endonovo Therapeutics, Inc.
ENDV - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$180.76K
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $180,756.00 |
|---|---|
| Enterprise Value | $7.19 Million |
| Earnings per Share | $0 |
| Beta | -8.36 |
| Outstanding Shares | 1,807,556,313 |
Return
| Return on Equity | 7.52% |
|---|---|
| Return on Assets | -5040.24% |
| Return on Invested Capital | 3.41% |
Valuation & Multiples
| P/E Ratio | -0.2 |
|---|---|
| PEG | -3.66 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -7.03 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.98 |
| Debt to Equity | -0.23 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Endonovo Therapeutics, Inc.
1 employees
CEO: Alan Brian Collier
Endonovo Therapeutics, Inc., a biotechnology company, specializes in the development, manufacturing, and distribution of non-invasive electroceutical medical devices designed for regenerative medicine applications. The company's primary ...